Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) Bundle
Who's behind Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (603707.SS) and why are they buying in? With insiders holding roughly 51% of the company as of February 14, 2025, and the top three shareholders-Ju Hua Xie (27%), Jiangsu Coast Development Group Co., Ltd. (21%), and Yongqun Tang (20%)-collectively owning 68%, the ownership structure signals concentrated control and aligned insider confidence; institutional participation is mixed, noted at about 12% earlier in 2025 with signatures from major players like Vanguard's VGTSX and VEIEX, while a September 15, 2025 snapshot records 19 institutions holding 1,740,255 shares (~0.11% of shares outstanding) and average allocations of 0.0026%, underscoring modest but notable external interest; operationally, the company's emphasis on high-end injectables, heparin derivatives and exports to Europe and America pairs with recent ANDA approvals and buybacks to shape market sentiment as the stock trades at CNY 9.17 (Dec 12, 2025), down 36.32% year-over-year, with a market cap of CNY 14.82 billion, a P/E of 22.82, beta 0.65 and a 1.09% dividend yield-read on to unpack who gains, who risks, and where prospective investors might find opportunity.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Who Invests in Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) and Why?
Nanjing King-Friend attracts a mix of large individual shareholders, state/strategic holders and selective institutional investors drawn by its specialization in high-end injectable pharmaceuticals, heparin derivatives and strong export footprint to Europe and North America. As of February 14, 2025, reported ownership concentrations and investor types include notable insider conviction alongside measured external participation.- Insiders/individuals: ~51% (indicating strong internal confidence and alignment with long‑term company growth).
- Top three named shareholders: Ju Hua Xie 27%, Jiangsu Coast Development Group Co., Ltd. 21%, Yongqun Tang 20% - collectively 68%.
- Institutional investors: ~12% (select, diversified exposure rather than broad passive accumulation).
| Shareholder | Stake (%) | Type | Notes |
|---|---|---|---|
| Ju Hua Xie | 27% | Individual | Major insider stake |
| Jiangsu Coast Development Group Co., Ltd. | 21% | State/Strategic | Regional strategic investor |
| Yongqun Tang | 20% | Individual | Senior individual shareholder |
| Insiders (aggregate) | ~51% | Individuals/Management | Significant insider ownership reported 14‑Feb‑2025 |
| Institutions (aggregate) | ~12% | Institutional funds | Includes international Vanguard funds and others |
| Vanguard Total International Stock Index Fund (VGTSX) | (reported holder) | Institutional | Provides diversified international exposure |
| Vanguard Emerging Markets Stock Index Fund (VEIEX) | (reported holder) | Institutional | Exposure to emerging-market pharmaceutical names |
- Why individuals/insiders hold large stakes: direct control, confidence in long‑term margins from specialized injectables and heparin derivative franchises, and influence over strategic export expansion.
- Why strategic/state investor participation matters: supports local industrial policy alignment and may facilitate export channels and regulatory navigation for Europe/US markets.
- Why institutional investors (including VGTSX, VEIEX) participate: portfolio diversification into global pharmaceuticals, exposure to specialized therapeutics with stable demand (antithrombotic/heparin products) and growth from high‑end injectable manufacturing.
- Why the company's product mix attracts capital: heparin derivatives address chronic thrombotic conditions (stable global demand), high regulatory barriers to entry protect margins, and established export relationships to Europe/America reduce single‑market risk.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) Institutional Ownership and Major Shareholders of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS)
As of September 15, 2025, institutional presence in Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) is limited but notable - 19 institutional investors collectively hold 1,740,255 shares, representing approximately 0.11% of shares outstanding. The profile of holders includes broad-market Vanguard funds, signaling diversified, passive exposure alongside active positions.- Institutional investors: 19
- Total institutional shares: 1,740,255
- Institutional ownership as % of outstanding shares: ~0.11%
- Average institutional portfolio allocation to the company: 0.0026%
- Notable institutional holders: Vanguard Total International Stock Index Fund (VGTSX) and Vanguard Emerging Markets Stock Index Fund (VEIEX)
- Largest institutional shareholder: VGTSX (identified as the largest institutional position among reported holders)
- Interpretation: presence of diversified Vanguard funds implies passive/global-index-driven exposure plus potential signaling to other institutions
| Metric | Value |
|---|---|
| Number of institutional investors | 19 |
| Total institutional shares held | 1,740,255 |
| Institutional ownership (% of shares outstanding) | 0.11% |
| Average institutional portfolio allocation | 0.0026% |
| Representative large holders | VGTSX (largest institutional holder), VEIEX |
- Credibility and stability: Multiple institutional names (including VGTSX/VEIEX) provide baseline credibility that can help attract further institutional attention as operational and financial metrics evolve.
- Room for institutional growth: At ~0.11% institutional ownership, peer comparisons suggest potential upside if growth, governance, or liquidity metrics improve.
- Investor behavior drivers: Passive fund exposure (VGTSX/VEIEX) indicates that continued inclusion in international/emerging-market index baskets could sustain or expand holdings independent of short-term fundamentals.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) - Key Investors and Their Impact on Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) Key Investors and Their Impact
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) exhibits concentrated ownership. Three principal shareholders-Ju Hua Xie, Jiangsu Coast Development Group Co., Ltd., and Yongqun Tang-collectively control 68% of outstanding shares, creating a governance structure where strategic direction and major corporate decisions can be strongly influenced by a small group of insiders.
- Ju Hua Xie - 27%: largest individual shareholder; strong personal stake that can shape board composition, executive appointments, dividend policy, and long-term R&D investment priorities.
- Jiangsu Coast Development Group Co., Ltd. - 21%: state/regionally linked strategic investor likely to provide capital access, regulatory navigation, and potential industrial partnerships or procurement advantages.
- Yongqun Tang - 20%: significant personal holding that suggests operational involvement or alignment with management strategy.
| Investor | Ownership (%) | Likely Influence / Role | Implications for Minority Holders |
|---|---|---|---|
| Ju Hua Xie | 27% | Voting power on major resolutions; potential board representation; long-term strategic alignment | Minority voice limited; potential stability if aligned with growth |
| Jiangsu Coast Development Group Co., Ltd. | 21% | Access to regional resources, regulatory support, and strategic partnerships | Can improve operational resilience; raises expectation of state-linked support |
| Yongqun Tang | 20% | Substantial personal investment; possible executive/operational influence | Signals insider confidence; may prioritize long-term initiatives over short-term payouts |
| Combined Top 3 | 68% | High voting concentration enabling coordinated strategic decisions, potential for rapid decision-making and reduced takeover risk | |
Key investor-driven effects to monitor:
- Alignment of management incentives with majority holders - likely emphasis on long-term growth and stability given large insider stakes.
- Potential for preferential contracts or financing via Jiangsu Coast Development Group, which can lower capital costs or accelerate projects.
- Governance risk: high insider control may constrain minority shareholder influence and reduce liquidity in contested strategic shifts.
- Market signaling: large personal investments by Xie and Tang enhance perceived insider confidence and may attract institutional investors seeking aligned ownership.
For the company's stated strategic framework and forward-looking positioning, see: Mission Statement, Vision, & Core Values (2026) of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) Market Impact and Investor Sentiment
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) hit CNY 9.17 per share as of December 12, 2025, down 36.32% year-over-year, a decline that has materially cooled short-term sentiment despite operational positives. The stock's market capitalization of CNY 14.82 billion and P/E ratio of 22.82 suggest the market values the company's earnings at a moderate multiple, while a beta of 0.65 signals lower systemic volatility that can attract investors seeking defensive exposure in healthcare. The dividend yield of 1.09% provides a modest income component but is unlikely on its own to drive significant inflows.- Price (12-Dec-2025): CNY 9.17
- 1Y Price Change: -36.32%
- Market Cap: CNY 14.82 billion
- P/E Ratio: 22.82
- Beta: 0.65
- Dividend Yield: 1.09%
- Positive catalysts: ANDA approvals in the U.S., strategic buybacks, and a clear push into high-end formulations and international markets.
- Negative drivers: steep Y/Y share decline, broader biotech sector risk-off, and competition pressure on margins.
- Investor profiles attracted: risk-averse dividend seekers, value investors watching post-decline recovery, and specialized pharma funds focused on product approvals and pipeline commercialization.
| Metric | Value | Implication |
|---|---|---|
| Stock Price (12-Dec-2025) | CNY 9.17 | Reflects market re-pricing after a 36.32% Y/Y fall |
| Market Capitalization | CNY 14.82 billion | Mid-cap positioning in A-share pharma space |
| P/E Ratio | 22.82 | Moderate valuation; earnings-based investors may find it reasonable |
| Beta | 0.65 | Lower volatility-appeals to defensive investors |
| Dividend Yield | 1.09% | Modest income; supplementary to capital appreciation |
| Key Corporate Actions | Stock repurchase programs; ANDA approvals | Supports confidence in cash returns and U.S. market entry |
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.